ATE294863T1 - Neuartige vegf-ähnliche faktoren - Google Patents

Neuartige vegf-ähnliche faktoren

Info

Publication number
ATE294863T1
ATE294863T1 AT97930804T AT97930804T ATE294863T1 AT E294863 T1 ATE294863 T1 AT E294863T1 AT 97930804 T AT97930804 T AT 97930804T AT 97930804 T AT97930804 T AT 97930804T AT E294863 T1 ATE294863 T1 AT E294863T1
Authority
AT
Austria
Prior art keywords
vegf
gene
isolated
protein
novel
Prior art date
Application number
AT97930804T
Other languages
English (en)
Inventor
Yuichi Hirata
Junichi Nezu
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16166915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE294863(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE294863T1 publication Critical patent/ATE294863T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT97930804T 1996-07-15 1997-07-15 Neuartige vegf-ähnliche faktoren ATE294863T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18521696 1996-07-15
PCT/JP1997/002456 WO1998002543A1 (fr) 1996-07-15 1997-07-15 Nouveaux facteurs analogues au vegf

Publications (1)

Publication Number Publication Date
ATE294863T1 true ATE294863T1 (de) 2005-05-15

Family

ID=16166915

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97930804T ATE294863T1 (de) 1996-07-15 1997-07-15 Neuartige vegf-ähnliche faktoren

Country Status (8)

Country Link
US (4) US6828426B1 (de)
EP (1) EP0935001B2 (de)
JP (1) JP3911028B2 (de)
AT (1) ATE294863T1 (de)
AU (1) AU733322B2 (de)
DE (1) DE69733204T3 (de)
ES (1) ES2242227T5 (de)
WO (1) WO1998002543A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
DK0848755T4 (da) * 1995-09-08 2011-05-23 Genentech Inc VEGF relateret protein
ATE290077T1 (de) 1995-09-29 2005-03-15 Univ Siena Regulierte gene und ihre verwendungen
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
AU733322B2 (en) * 1996-07-15 2001-05-10 Chugai Seiyaku Kabushiki Kaisha Novel VEGF-like factor
DE69734359T2 (de) * 1996-08-23 2006-07-06 Ludwig Institute For Cancer Research Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7947472B2 (en) 1997-12-24 2011-05-24 Vegenics Limited Expression vectors and cell lines expressing vascular endothelial growth factor D
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
CN1330555A (zh) * 1998-12-21 2002-01-09 路德维格癌症研究所 抗截短的vegf－d的抗体及其应用
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
US6764820B2 (en) * 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
JP4981229B2 (ja) 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
CA2401665A1 (en) * 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
DK1259248T3 (da) * 2000-03-02 2005-04-11 Ludwig Inst Cancer Res Fremgangsmåde til behandling af cancere, der udtrykker vaskulær endotelvækstfaktor D
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
AU2006201128B2 (en) * 2000-03-02 2009-05-28 Vegenics Limited Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D
EP2275557A1 (de) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albuminfusionsproteine
AU2001264565B2 (en) * 2000-05-03 2006-12-07 Vegenics Limited A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
JP2004537260A (ja) 2000-12-07 2004-12-16 サンガモ バイオサイエンシーズ， インコーポレイテッド ジンクフィンガータンパク質による血管新生の調節
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
EP2990417A1 (de) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin-insulin-fusionsprotein
EP2070949B1 (de) 2002-06-10 2013-01-16 Vaccinex, Inc. C35-Antikörper und ihre Verwendung zur Behandlung von Krebs
US20060024302A1 (en) 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
EP1919944B1 (de) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
KR101642846B1 (ko) 2007-12-26 2016-07-26 백시넥스 인코포레이티드 항-ｃ35 항체 병용 치료 및 방법
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
MY170528A (en) 2013-02-18 2019-08-09 Vegenics Pty Ltd Vegfr-3 ligand binding molecules and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
ATE281469T1 (de) 1993-03-25 2004-11-15 Merck & Co Inc Inhibitor des wachstumsfaktors für gefäss- endothelzellen
EP0721015B1 (de) 1993-09-03 2004-10-27 Chugai Seiyaku Kabushiki Kaisha Apoptose induzierender monoklonaler antikörper
DK0751992T3 (da) * 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
DK0848755T4 (da) 1995-09-08 2011-05-23 Genentech Inc VEGF relateret protein
ATE290077T1 (de) * 1995-09-29 2005-03-15 Univ Siena Regulierte gene und ihre verwendungen
AU733322B2 (en) 1996-07-15 2001-05-10 Chugai Seiyaku Kabushiki Kaisha Novel VEGF-like factor
DE69734359T2 (de) 1996-08-23 2006-07-06 Ludwig Institute For Cancer Research Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
AU5439998A (en) * 1996-12-06 1998-06-29 Zymogenetics Inc. Vascular endothelial growth factor

Also Published As

Publication number Publication date
US6828426B1 (en) 2004-12-07
AU733322B2 (en) 2001-05-10
DE69733204T3 (de) 2012-03-08
ES2242227T3 (es) 2005-11-01
EP0935001B2 (de) 2011-08-10
US20110293602A1 (en) 2011-12-01
DE69733204D1 (de) 2005-06-09
US7803576B2 (en) 2010-09-28
AU3461097A (en) 1998-02-09
EP0935001A1 (de) 1999-08-11
EP0935001B9 (de) 2007-01-24
ES2242227T5 (es) 2011-12-09
DE69733204T2 (de) 2006-05-11
EP0935001A4 (de) 2000-08-23
WO1998002543A1 (fr) 1998-01-22
JP3911028B2 (ja) 2007-05-09
EP0935001B1 (de) 2005-05-04
US20060172343A1 (en) 2006-08-03
US20050112665A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
ATE294863T1 (de) Neuartige vegf-ähnliche faktoren
Kreiss et al. Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer
DK288183D0 (da) Fremgangsmade til fremstilling af et oligonucleotidt terapeutisk middel
NL990033I1 (nl) Tumornecrosefactor, werkwijzen om het te bereiden,samenstellingen die het bevatten, DNA dat ervoor codeert en proefmethoden met dergelijk DNA.
AU6847298A (en) Transcription factor islet-brain 1 (ib1)
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
DK0814827T3 (da) Karendotel-vækstfaktor-B
Gao et al. Gene therapy for obesity: progress and prospects
HUP9903921A2 (hu) Tumor nekrózis faktorral rokon ligandum
WO2003023000A3 (en) Linear dna fragments for gene expression
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
MY142457A (en) Plasmid mediated supplementation for treating chronically ill subjects
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
WO1998011234A3 (en) Human protein kinases
WO2002050111A3 (en) Isolated laminin 10
CA2260754A1 (en) Novel vegf-like factor
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
Janarthini et al. A Tobacco‐Derived Thymosin β4 Concatemer Promotes Cell Proliferation and Wound Healing in Mice
ATE91717T1 (de) Verfahren zur herstellung von proteinen in loeslicher form.
AU698242B2 (en) Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
ATE447415T1 (de) Ghrh zur verwendung bei der behandlung von chronischer niereninsuffizienz
WO2000005416A3 (en) Fgf-bp promoter sequences as sensors of drug effects
WO1998012220A3 (en) Novel tumor proteins
EP0787798A3 (de) GRP17 Gen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties